📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Stock jumps 5% after company’s net profit increases by 27% QoQ

Published 08-08-2024, 01:49 pm
Updated 08-08-2024, 03:45 pm
Stock jumps 5% after company’s net profit increases by 27% QoQ
LPLA
-

Shares of a leading pharmaceutical firm rose by 5% to ₹693 per share on Thursday, following the company’s announcement of a 24% increase in net profit for the June quarter.

At 1:05 p,m., Lincoln Pharmaceuticals Ltd shares were trading at ₹680.65 per share, up 3.29 percent from the previous close price on the exchange. The company has a market capitalization of ₹1,378 crore.

Is Lincoln Pharmaceuticals a buy or sell? What is its Fair Value? What are the company's health parameters? What are the positive and negative factors driving the company -- ProTips? Know all the answers on the company's overview page here.

What Happened:

Lincoln Pharmaceuticals Ltd’s exchange filings revealed a robust financial performance for Q1 FY25, with a consolidated net profit of ₹23.5 crores, representing a 24% year-over-year increase. The company’s total revenue for the quarter amounted to ₹147 crores, a 9% rise from the same period last year.

On a quarter-on-quarter basis, the company’s net profit surged by 27%, while revenue grew by 3.5%. Additionally, on a standalone basis, the company’s EBITDA increased by 16.65% year-over-year.

Looking ahead, driven by its growth strategies and expansion into value-added products and new markets, the company aims to achieve a revenue target of ₹750 crores in FY26.

As of June 2024, Foreign Institutional Investors (FIIs) have incrementally increased their stake in the company to 3.95%, up from 1.74% in June 2023. Meanwhile, promoters hold a 49.78% stake, and retail investors possess 46.24% of the shares.

About the company:

Lincoln Pharmaceuticals Limited (LPL) specializes in the manufacturing, marketing, and distribution of pharmaceutical products. The company has developed over 600 formulations across 15 therapeutic areas and has 1,700 registered products, with an additional 700 in development.

Over the past five years, LPL has achieved a compound annual growth rate (CAGR) of more than 13% in profits and sustained single-digit sales growth. Profit margins have increased from approximately 13% in FY19 to over 16% in FY24. Notably, LPL is among a select few companies to have realized profit growth every year from FY13 to FY23.

LPL’s export market spans over 60 countries, including East and West Africa, Central and North America, Latin America, and Southeast Asia. The company recently expanded into the Canadian market.

In the last six months, LPL’s shares have risen by 2%, and over the past 12 months, they have increased by 48%.

Written by Omkar Chitnis

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Stock jumps 5% after company’s net profit increases by 27% QoQ appeared first on Trade Brains.

Read More

To understand more about InvestingPro, watch this video: https://www.youtube.com/watch?v=_WfQcN5vjIE

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.